
Definium Therapeutics, Inc.: shareholders and insiders
Price
$29.38
November 17, 2026Market cap $4.0B
What Ploutos Investor adds for Definium Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 6 fiscal years, from 2020
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.
Insiders and their shares
Purchases and sales by officers and directors from Nov 18, 2025 to Sep 29, 2026, from their own Form 4 filings.
Bought on the market
–
nobody
Sold on the market
$7.0M
5 people
From Nov 18, 2025 to Nov 18, 2026, the days the chart shows. Change its range and the figures follow.
How the sales were made, as a share of their value
- Under a set plan100%
- The rest0%
By year
Insiders' open-market purchases (up) and sales (down), by value, since Nov 18, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.
2026·no buys·sold $6.4M by 5 people
- 2025: no buys, sold $561.1K by 3 people
- 2026: no buys, sold $6.4M by 5 people
- Sep 25, 2026Daniel KarlinChief Medical OfficerKind10b5-1
- Sep 25, 2026Robert BarrowChief Executive OfficerKind10b5-1
- Sep 25, 2026Matthew T. WileyChief Commercial OfficerKind10b5-1
- Sep 25, 2026Mark SullivanChief Legal OfficerKind10b5-1
- Sep 25, 2026Brandi RobertsChief Financial OfficerKind10b5-1
- Sep 18, 2026Carol A ValloneDirectorKind
- Sep 18, 2026Andreas KrebsDirectorKind
- Sep 14, 2026Daniel KarlinChief Medical OfficerKind
- Sep 14, 2026Matthew T. WileyChief Commercial OfficerKind
- Sep 14, 2026Mark SullivanChief Legal OfficerKind
- Sep 14, 2026Brandi RobertsChief Financial OfficerKind
- Sep 14, 2026Robert BarrowChief Executive OfficerKind
- Sep 3, 2026Robert BarrowChief Executive OfficerKind10b5-1
- Sep 2, 2026Robert BarrowChief Executive OfficerKind10b5-1
- Aug 12, 2026Robert BarrowChief Executive OfficerKind
- Aug 12, 2026Daniel KarlinChief Medical OfficerKind
- Aug 12, 2026Mark SullivanChief Legal OfficerKind
- Aug 12, 2026Matthew T. WileyChief Commercial OfficerKind
- Aug 12, 2026Brandi RobertsChief Financial OfficerKind
- Jun 25, 2026Mark SullivanChief Legal OfficerKind10b5-1
- Jun 25, 2026Brandi RobertsChief Financial OfficerKind10b5-1
- Jun 25, 2026Robert BarrowChief Executive OfficerKind10b5-1
- Jun 25, 2026Daniel KarlinChief Medical OfficerKind10b5-1
- Jun 25, 2026Matthew T. WileyChief Commercial OfficerKind10b5-1
- Jun 22, 2026Matthew T. WileyChief Commercial OfficerKind
| Date | Person | Kind | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 25, 2026 | Daniel KarlinChief Medical Officer | 10b5-1 | 10.9K | $36.57 | $396.9K | Form 4 |
| Sep 25, 2026 | Robert BarrowChief Executive Officer | 10b5-1 | 31.6K | $36.57 | $1.2M | Form 4 |
| Sep 25, 2026 | Matthew T. WileyChief Commercial Officer | 10b5-1 | 3,097 | $36.57 | $113.3K | Form 4 |
| Sep 25, 2026 | Mark SullivanChief Legal Officer | 10b5-1 | 14.1K | $36.57 | $513.8K | Form 4 |
| Sep 25, 2026 | Brandi RobertsChief Financial Officer | 10b5-1 | 3,377 | $36.57 | $123.5K | Form 4 |
| Sep 18, 2026 | Carol A ValloneDirector | 1,086 | $35.52 | $38.6K | Form 4 | |
| Sep 18, 2026 | Andreas KrebsDirector | 1,629 | $35.52 | $57.9K | Form 4 | |
| Sep 14, 2026 | Daniel KarlinChief Medical Officer | 200.0K | – | – | Form 4 | |
| Sep 14, 2026 | Matthew T. WileyChief Commercial Officer | 125.0K | – | – | Form 4 | |
| Sep 14, 2026 | Mark SullivanChief Legal Officer | 125.0K | – | – | Form 4 | |
| Sep 14, 2026 | Brandi RobertsChief Financial Officer | 125.0K | – | – | Form 4 | |
| Sep 14, 2026 | Robert BarrowChief Executive Officer | 750.0K | – | – | Form 4 | |
| Sep 3, 2026 | Robert BarrowChief Executive Officer | 10b5-1 | 19.0K | $37.94 | $721.7K | Form 4 |
| Sep 2, 2026 | Robert BarrowChief Executive Officer | 10b5-1 | 40.0K | – | – | Form 4 |
| Aug 12, 2026 | Robert BarrowChief Executive Officer | 375.0K | – | – | Form 4 | |
| Aug 12, 2026 | Daniel KarlinChief Medical Officer | 100.0K | – | – | Form 4 | |
| Aug 12, 2026 | Mark SullivanChief Legal Officer | 62.5K | – | – | Form 4 | |
| Aug 12, 2026 | Matthew T. WileyChief Commercial Officer | 62.5K | – | – | Form 4 | |
| Aug 12, 2026 | Brandi RobertsChief Financial Officer | 62.5K | – | – | Form 4 | |
| Jun 25, 2026 | Mark SullivanChief Legal Officer | 10b5-1 | 13.0K | $45.03 | $585.8K | Form 4 |
| Jun 25, 2026 | Brandi RobertsChief Financial Officer | 10b5-1 | 3,013 | $45.03 | $135.7K | Form 4 |
| Jun 25, 2026 | Robert BarrowChief Executive Officer | 10b5-1 | 29.2K | $45.03 | $1.3M | Form 4 |
| Jun 25, 2026 | Daniel KarlinChief Medical Officer | 10b5-1 | 10.0K | $45.03 | $451.9K | Form 4 |
| Jun 25, 2026 | Matthew T. WileyChief Commercial Officer | 10b5-1 | 2,867 | $45.03 | $129.1K | Form 4 |
| Jun 22, 2026 | Matthew T. WileyChief Commercial Officer | 62.5K | – | – | Form 4 |
From the Form 4s insiders file with the SEC within two business days of each trade. Before Jun 15, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.
Insiders and their shares
Every buy and sale by DFTX's officers and directors from 2022 up to November 17, 2025, 4 more calendar years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 3 years.
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- BlackRock, Inc.Share of class8.30%
- FMRwith 1 more personShare of class6.50%
- Driehaus Capital ManagementShare of class5.36%
- Avoro Capital Advisors LLCwith 1 more personCommon Shares, no par value per shareShare of class5.08%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| BlackRock, Inc. | 8.30% | 6.07M | Feb 5, 2025 | 13G/A | |
| FMRwith 1 more person | 6.50% | 8.79M | Nov 5, 2026 | 13G | |
| Driehaus Capital Management | 5.36% | 6.85M | Aug 14, 20262 filings since Feb 17, 2026 | 13G/A | |
| Avoro Capital Advisors LLCwith 1 more personCommon Shares, no par value per share | 5.08% | 5.00M | Feb 17, 2026 | 13G |
Fell to 5% or less (2)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Duquesne (Druckenmiller)In the quarter
- Citadel Advisors (Griffin)In the quarter
- Point72 (Cohen)In the quarter
- Millennium Mgmt (Englander)In the quarter-85%
- D.E. ShawIn the quarter-49%
- AQR CapitalIn the quarter+36%
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Duquesne (Druckenmiller) | – | – | 0.39% | |
| Citadel Advisors (Griffin) | – | – | 0.05% | |
| Point72 (Cohen) | – | – | 0.03% | |
| Millennium Mgmt (Englander) | 40.5K | -85% | $1.5M | 0.00% |
| D.E. Shaw | 159.3K | -49% | $6.1M | 0.00% |
| AQR Capital | 182.9K | +36% | $7.0M | 0.00% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 7.34% of its shares outstanding were held short, -11.5% since the report before.
- Shares held short
- 10.04M
- 7.34%
- Since the report before11.34M on Sep 30, 2026
- -11.5%
- 4.9
- 2.06M
- More days to cover thanof 4,578 US-listed companies with enough volume
- 59%
- Report date
- Oct 15, 2026
- Shares held short
- Jan 15, 2026: Shares held short 16.83M
- Jan 30, 2026: Shares held short 17.67M
- Feb 13, 2026: Shares held short 19.51M
- Feb 27, 2026: Shares held short 19.34M
- Mar 13, 2026: Shares held short 15.01M
- Mar 31, 2026: Shares held short 15.13M
- Apr 15, 2026: Shares held short 9.82M
- Apr 30, 2026: Shares held short 9.36M
- May 15, 2026: Shares held short 9.25M
- May 29, 2026: Shares held short 9.43M
- Jun 15, 2026: Shares held short 10.64M
- Jun 30, 2026: Shares held short 14.52M
- Jul 15, 2026: Shares held short 10.64M
- Jul 31, 2026: Shares held short 10.74M
- Aug 14, 2026: Shares held short 8.97M
- Aug 31, 2026: Shares held short 9.84M
- Sep 15, 2026: Shares held short 11.79M
- Sep 30, 2026: Shares held short 11.34M
- Oct 15, 2026: Shares held short 10.04M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading66.3% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 66.3% of the shares in the reported trades were short sales, against 63.8% in the 14 before.
- Last 14 sessionsOct 29, 2026 – Nov 17, 2026
- 66.3%
- The 14 beforeOct 9, 2026 – Oct 28, 2026
- 63.8%
- Change
- +2.5 pts
- Short sales a dayon average, of 687.6K shares
- 455.9K
- More than atof 3,666 US-listed companies, same days
- 94%
- Median of alleight in ten from 34.6% to 63.7%
- 50.3%
- Short sales
- Oct 9, 2026: Short sales 64.7%
- Oct 12, 2026: Short sales 35%
- Oct 13, 2026: Short sales 64.1%
- Oct 14, 2026: Short sales 44.8%
- Oct 15, 2026: Short sales 67.9%
- Oct 16, 2026: Short sales 57.4%
- Oct 19, 2026: Short sales 56.1%
- Oct 20, 2026: Short sales 69.2%
- Oct 21, 2026: Short sales 82.8%
- Oct 22, 2026: Short sales 77.3%
- Oct 23, 2026: Short sales 75.4%
- Oct 26, 2026: Short sales 69.4%
- Oct 27, 2026: Short sales 66.3%
- Oct 28, 2026: Short sales 68.2%
- Oct 29, 2026: Short sales 71.4%
- Oct 30, 2026: Short sales 52.2%
- Nov 2, 2026: Short sales 68.4%
- Nov 3, 2026: Short sales 65.4%
- Nov 4, 2026: Short sales 68.2%
- Nov 5, 2026: Short sales 62.6%
- Nov 6, 2026: Short sales 69.7%
- Nov 9, 2026: Short sales 71.3%
- Nov 10, 2026: Short sales 75.8%
- Nov 11, 2026: Short sales 82.7%
- Nov 12, 2026: Short sales 65.8%
- Nov 13, 2026: Short sales 60.9%
- Nov 16, 2026: Short sales 65.9%
- Nov 17, 2026: Short sales 49.3%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
- Robert BarrowChief Executive OfficerDirectly2.21M
- Daniel KarlinChief Medical OfficerDirectly792.8K
- Mark SullivanChief Legal OfficerDirectly494.2K
- Brandi RobertsChief Financial OfficerDirectly394.5K
- Matthew T. WileyChief Commercial OfficerDirectly359.0K
- Schond L. GreenwayChief Financial OfficerDirectly216.6K
- Carrie LiaoChief Accounting OfficerDirectly144.9K
- Roger CrystalDirectorDirectly24.3K
- Suzanne Louise BruhnDirectorDirectly24.3K
- Carol A ValloneDirectorDirectly22.3K
- Andreas KrebsDirectorDirectly21.4K
- David W GryskaDirectorDirectly19.9K
- Roger AdsettDirectorDirectly3,555
| Person | Directly | Indirectly | After the trade of | Filing |
|---|---|---|---|---|
| Robert BarrowChief Executive Officer | 2.21M | – | Sep 25, 2026 | Form 4 |
| Daniel KarlinChief Medical Officer | 792.8K | – | Sep 25, 2026 | Form 4 |
| Mark SullivanChief Legal Officer | 494.2K | – | Sep 25, 2026 | Form 4 |
| Brandi RobertsChief Financial Officer | 394.5K | – | Sep 25, 2026 | Form 4 |
| Matthew T. WileyChief Commercial Officer | 359.0K | – | Sep 25, 2026 | Form 4 |
| Schond L. GreenwayChief Financial Officer | 216.6K | – | Dec 26, 2023 | Form 4 |
| Carrie LiaoChief Accounting Officer | 144.9K | – | Mar 25, 2025 | Form 4 |
| Roger CrystalDirector | 24.3K | – | Jun 11, 2026 | Form 4 |
| Suzanne Louise BruhnDirector | 24.3K | – | Jun 11, 2026 | Form 4 |
| Carol A ValloneDirector | 22.3K | – | Sep 18, 2026 | Form 4 |
| Andreas KrebsDirector | 21.4K | – | Sep 18, 2026 | Form 4 |
| David W GryskaDirector | 19.9K | – | Jun 11, 2026 | Form 4 |
| Roger AdsettDirector | 3,555 | – | Jun 11, 2026 | Form 4 |
A lower bound: it counts only the 13 officers and directors with a market trade since Nov 19, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
The ETFs that hold it
Which of the 345 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- IHEiShares U.S. Pharmaceuticals ETFWeight in the fund1.39%
- IBBiShares Biotechnology ETFWeight in the fund0.38%
- IWOiShares Russell 2000 Growth ETFWeight in the fund0.36%
- FESMFidelity Enhanced Small Cap Core ETFWeight in the fund0.30%
- IWMiShares Russell 2000 ETFWeight in the fund0.19%
- VTWOVanguard Russell 2000 Index FundWeight in the fund0.17%
- SCHASchwab U.S. Small-Cap ETFWeight in the fund0.11%
- VXFVanguard Extended Market Index FundWeight in the fund0.07%
- FBCGFidelity Blue Chip Growth ETFWeight in the fund0.06%
- VHTVanguard Health Care Index FundWeight in the fund0.06%
14 of the 345 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q4 2025: Managers 8
- Q1 2026: Managers 245
- Q2 2026: Managers 360
Q2 2026: 360 managers held 115M shares, worth $5.3B. During the quarter 149 opened a position, 34 closed one, 110 added and 64 trimmed.
The largest holders, Q2 2026
- BlackRockIn the quarter+32%
- Avoro Capital AdvisorsIn the quarter+44%
- Driehaus Capital ManagementIn the quarter+16%
- Jupiter TopcoIn the quarter
- Capital World InvestorsIn the quarter
- FMRIn the quarter+163%
- Price T Rowe AssociatesIn the quarter×66.5
- Geode Capital ManagementIn the quarter+46%
- State StreetIn the quarter+24%
- Capital International InvestorsIn the quarter
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| BlackRock | 11.23M | +32% | $528M |
| Avoro Capital Advisors | 7.19M | +44% | $338M |
| Driehaus Capital Management | 6.85M | +16% | $322M |
| Jupiter Topco | 5.62M | $264M | |
| Capital World Investors | 5.37M | $252M | |
| FMR | 4.75M | +163% | $224M |
| Price T Rowe Associates | 4.65M | ×66.5 | $219M |
| Geode Capital Management | 3.64M | +46% | $171M |
| State Street | 3.07M | +24% | $144M |
| Capital International Investors | 2.96M | $139M |
From the SEC's Form 13F data sets, Q4 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do Definium Therapeutics's filings show?
Who buys and sells is one part of Definium Therapeutics's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have DFTX's insiders bought or sold?
From Jun 15, 2026 to Sep 29, 2026 Definium Therapeutics's insiders bought 0 and sold $5.6M of shares on the market. 100% of the sales were under set 10b5-1 plans.
Which well-known managers hold DFTX?
6 of the managers we track held the shares on Sep 30, 2026. The largest position was AQR Capital's, worth $7.0M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.